Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLC

(MedPage Today) -- CHICAGO -- In patients with metastatic EGFR-positive lung cancer who progressed on targeted agents, adding pembrolizumab (Keytruda) to a standard chemotherapy regimen demonstrated no survival benefit, a randomized trial found...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news